Al in Biotechnology Market

The global AI in Biotechnology market is projected to reach USD 7.75 billion by 2029 from USD 3.23 billion in 2024, at a high CAGR of 19.1% during the forecast period. Increasing cross-industry collaborations and partnerships that foster innovation and resource sharing are the main reasons for the growth of this market. High penetration of AI-powered biomarker discovery for complex diseases, rising utilization of AI in digital twins for drug discovery, and AI and CRISPR-Cas9 synergy in genetic drug discovery are some of the other factors propelling market growth. However, several factors will likely restrain market growth such as fragmented global regulations for AI, lack of sufficient AI infrastructure in developing economies, and difficulties in applying ai-generated knowledge to clinical settings are some factors contributing to challenges in the market growth.

Prominent players in the AI in the biotechnology market include NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia plc (UK), Schrödinger, Inc. (US), Recursion Pharmaceuticals, Inc.  (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US), Deep Genomics. (Canada), Data4Cure, Inc. (US), Genoox (US), BenevolentAI (US), DNAnexus, Inc. (US), Tempus (US), NuMedii, Inc. (US), XtalPi Inc. (US), Lifebit Biotech Ltd (England), BPGbio, Inc. (US), Valo Health (US), VeriSIM Life. (US), Iktos. (France), Insilico Medicine (US), Eurofins Discovery. (US), Logica. (US), American Chemical Society (US), Aganitha AI Inc. (India).

To know about the assumptions considered for the study download the pdf brochure

These companies adopted strategies such as partnerships, collaborations, acquisitions, expansion, agreements, investment, and product launches to strengthen their market presence in the AI in Biotechnology market.

NVIDIA Corporation engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. Initially, the firm was primarily operating in graphics hardware for gaming, but through time, over the recent years, NVIDIA has been more focused towards applications of AI, machine learning, deep learning, and data science in a wide array of industries as well as into healthcare, for example. The company's GPUs have been known to provide better performance in AI computing; it thus formed the core of moving research that is driven by AI, including applications in medical imaging and digital pathology. NVIDIA is making deep inroads in the healthcare sector by furthering the development of AI innovations using its NVIDIA Clara platform as an AI engine that offers AI tools and frameworks for medical imaging, genomics, and drug discovery. At the level of digital pathology, NVIDIA is utilizing GPUs and AI frameworks to facilitate accelerated image analysis and faster and more accurate diagnosis from pathology slides.The company operates in North America, South America, Asia Pacific, and Europe.

Illumina, Inc. is one of the leading providers of genomic solutions. The company delivers array-based life sciences technology and DNA sequencing to facilitate personalized health and advanced research & discovery. It offers products related to infectious diseases, genetics, reproductive health oncology, and others. Illumina has collaborated with several global payers such as AstraZeneca, Janssen, PRECISE, Bristol-Myers Squibb, Kura Oncology, Myriad Genetics, Merck, and others to expand their product portfolio and strengthen their position in the global market.

Exscientia plc is a drug design firm that effectively develops medications for illnesses with substantial unmet patient needs by utilizing artificial intelligence (AI) and innovative technologies. The company aims to improve the probability of successful medication development by identifying and addressing potential causes of failure in the drug design process. Exscientia's technological platform includes several innovative methods, including generative Al, active learning, machine learning, and physics-based systems.

Related Reports:

Al in Biotechnology Market by Function (Drug Design & Optimisation, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events), & End User - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]